GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster

Stock Information for GeoVax Labs Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About GeoVax Labs Inc.

GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress
GeoVax to Present at the 36th Annual Roth Conference
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
GeoVax Reports 2023 Year-End Financial Results and Provides Business Update
GeoVax to Present at the 2024 BIO CEO & Investor Conference
GeoVax Announces Multiple Patent Issuances and Allowances
GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.